Fig. 2From: Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort studyComparison of length of stay between groupsNote: “*” means p < 0.05, “**” means p < 0.01, “***” means P < 0.001, “ns” means not significantBack to article page